This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (86)  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in JAMA  Topic Collections  • Revascularization  • Evidence-Based Medicine  • Surgical Interventions  • Cardiovascular/ Cardiothoracic Surgery  • Vascular Surgery  • Review  • Randomized Controlled Trial  • Cardiovascular Disease/ Myocardial Infarction  • Cardiovascular Intervention  • Alert me on articles by topic

A Meta-analysis of Randomized Trials

Giuseppe De Luca, MD; Harry Suryapranata, MD, PhD; Gregg W. Stone, MD; David Antoniucci, MD; James E. Tcheng, MD; Franz-Josef Neumann, MD; Frans Van de Werf, MD; Elliott M. Antman, MD; Eric J. Topol, MD

JAMA. 2005;293:1759-1765.

Context  The benefits of abciximab in patients with ST-segment elevation myocardial infarction (STEMI) are still a matter of debate.

Objective  To combine data from all randomized trials conducted with abciximab in STEMI.

Data Sources  Formal searches of electronic databases (MEDLINE, PubMed) from from January 1990 to December 2004.

Study Selection  We examined all completed, published, randomized trials of abciximab in STEMI. The following key words were used for study selection: randomized trial, myocardial infarction, reperfusion, primary angioplasty, facilitated angioplasty, stenting, fibrinolysis, IIb-IIIa inhibitors, and abciximab.

Data Extraction  Information on study design, type and dosage of drugs, inclusion and exclusion criteria, number of patients, and clinical outcome was extracted by 2 investigators. Disagreements were resolved by consensus.

Data Synthesis  Eleven trials were analyzed, involving 27115 patients (12 602 [46.5%] in the abciximab group, 14 513 [53.5%] in the control group). When compared with the control group, abciximab was associated with a significant reduction in short-term (30 days) mortality (2.4% vs 3.4%, P = .047) and long-term (6-12 months) mortality (4.4% vs 6.2%, P = .01) in patients undergoing primary angioplasty but not in those treated with fibrinolysis or in all trials combined. Abciximab was associated with a significant reduction in 30-day reinfarction, both in all trials combined (2.1% vs 3.3%, P<.001), in primary angioplasty (1.0% vs 1.9%, P = .03), and in fibrinolysis trials (2.3% vs 3.6%, P<.001). Abciximab did not result in an increased risk of intracranial bleeding (0.61% vs 0.62%, P = .62) but was associated with an increased risk of major bleeding complications when combined with fibrinolysis (5.2% vs 3.1%, P<.001) but not with primary angioplasty (4.7% vs 4.1%, P = .36).

Conclusions  This meta-analysis shows that, when compared with the control group, adjunctive abciximab for STEMI is associated with a significant reduction in 30-day and long-term mortality in patients treated with primary angioplasty but not in those receiving fibrinolysis. The 30-day reinfarction rate is significantly reduced in patients treated with either fibrinolysis or primary angioplasty. A higher risk of major bleeding complications is observed with abciximab in association with fibrinolysis.

Author Affiliations: Isala Klinieken, Hospital De Weezenlanden, Zwolle, the Netherlands (Drs De Luca and Suryapranata); Cardiovascular Research Foundation, Lenox Hill Heart and Vascular Institute, New York, NY (Dr Stone); Division of Cardiology, Careggi Hospital, Florence, Italy (Dr Antoniucci); Duke Clinical Research Institute, Durham, NC (Dr Tcheng); Medizinische Klinik, Technische Universität Munchen, Munich, Germany (Dr Neumann); Department of Cardiology, Gasthuisberg University Hospital, Leuven, Belgium (Dr Van de Werf); Cardiovascular Division, Brigham and Women’s Hospital, Boston, Mass (Dr Antman); and Cleveland Clinic Foundation, Cleveland, Ohio (Dr Topol).

RELATED LETTERS

Abciximab in the Treatment of ST-Segment Elevation Myocardial Infarction
Daniel Shao-Weng Tan, David Kheng-Leng Sim, Edwin Shih-Yen Chan, and Ru-San Tan
JAMA. 2005;294(14):1760-1761.
EXTRACT | FULL TEXT  

Abciximab in the Treatment of ST-Segment Elevation Myocardial Infarction—Reply
Giuseppe De Luca and Harry Suryapranata
JAMA. 2005;294(14):1761.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The GPIIb/IIIa (integrin {alpha}IIb{beta}3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend
Coller and Shattil
Blood 2008;112:3011-3025.
ABSTRACT | FULL TEXT  

Adjunctive manual thrombectomy improves myocardial perfusion and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials
De Luca et al.
Eur Heart J 2008;0:ehn389v1-9.
ABSTRACT | FULL TEXT  

Angioplasty Strategies in ST-Segment-Elevation Myocardial Infarction: Part I: Primary Percutaneous Coronary Intervention
Stone
Circulation 2008;118:538-551.
FULL TEXT  

Intracoronary Compared With Intravenous Bolus Abciximab Application in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: The Randomized Leipzig Immediate Percutaneous Coronary Intervention Abciximab IV Versus IC in ST-Elevation Myocardial Infarction Trial
Thiele et al.
Circulation 2008;118:49-57.
ABSTRACT | FULL TEXT  

Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Goodman et al.
Chest 2008;133:708S-775S.
ABSTRACT | FULL TEXT  

Bivalirudin during Primary PCI in Acute Myocardial Infarction
Stone et al.
NEJM 2008;358:2218-2230.
ABSTRACT | FULL TEXT  

Antithrombotic Therapy to Support Primary PCI
Morrow
NEJM 2008;358:2280-2282.
FULL TEXT  

The Danish multicentre randomized study of fibrinolytic therapy vs. primary angioplasty in acute myocardial infarction (the DANAMI-2 trial): outcome after 3 years follow-up
Busk et al.
Eur Heart J 2008;29:1259-1266.
ABSTRACT | FULL TEXT  

Comparison of Angioplasty With Infusion of Tirofiban or Abciximab and With Implantation of Sirolimus-Eluting or Uncoated Stents for Acute Myocardial Infarction: The MULTISTRATEGY Randomized Trial
Valgimigli et al.
JAMA 2008;299:1788-1799.
ABSTRACT | FULL TEXT  

Should We Routinely Use Drug-Eluting Stents for Acute Myocardial Infarction?: Let's Wait and See
Grines et al.
J Am Coll Cardiol Intv 2008;1:136-138.
FULL TEXT  

The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention insights from a large regional registry of contemporary percutaneous coronary intervention.
Gurm et al.
J Am Coll Cardiol 2008;51:529-535.
ABSTRACT | FULL TEXT  

The safety and efficacy of glycoprotein IIb/IIIa inhibitors for primary angioplasty: more options to choose and more time to decide.
Moliterno and Ziada
J Am Coll Cardiol 2008;51:536-537.
FULL TEXT  

Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment
Oldgren et al.
Eur Heart J 2008;29:315-323.
ABSTRACT | FULL TEXT  

Primary Percutaneous Coronary Intervention
Kapoor et al.
NEJM 2008;358:431-433.
FULL TEXT  

Myocardial Revascularization with Percutaneous Devices
Wilson and Willerson
Card Surg Adult 2008;3:573-598.
FULL TEXT  

Ventricular septal rupture following abciximab infusion
Arnold et al.
Eur J Echocardiogr 2008;9:60-62.
ABSTRACT | FULL TEXT  

Antiplatelet therapy in acute coronary syndromes
Gitt and Betriu
Eur Heart J Suppl 2008;10:A4-A12.
ABSTRACT | FULL TEXT  

Field triage to primary angioplasty combined with emergency department bypass reduces treatment delays and is associated with improved outcome
Carstensen et al.
Eur Heart J 2007;28:2313-2319.
ABSTRACT | FULL TEXT  

Reperfusion Strategies in Acute ST-Segment Elevation Myocardial Infarction: A Comprehensive Review of Contemporary Management Options
Boden et al.
J Am Coll Cardiol 2007;50:917-929.
ABSTRACT | FULL TEXT  

Clinical Aspects of Platelet Inhibitors and Thrombus Formation
Meadows and Bhatt
Circ. Res. 2007;100:1261-1275.
ABSTRACT | FULL TEXT  

Randomized Early Versus Late Abciximab in Acute Myocardial Infarction Treated With Primary Coronary Intervention (RELAx-AMI Trial)
Maioli et al.
J Am Coll Cardiol 2007;49:1517-1524.
ABSTRACT | FULL TEXT  

A comprehensive view of sex-specific issues related to cardiovascular disease
Pilote et al.
CMAJ 2007;176:S1-S44.
ABSTRACT | FULL TEXT  

Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up
Montalescot et al.
Eur Heart J 2007;28:443-449.
ABSTRACT | FULL TEXT  

Cancer Care, Money, and the Value of Life: Whose Justice? Which Rationality?
Sulmasy
JCO 2007;25:217-222.
ABSTRACT | FULL TEXT  

Glycoprotein IIb/IIIa Inhibitors in the Elderly: Fear of Age or Age of Fear?
Montalescot
Circulation 2006;114:2004-2006.
FULL TEXT  

The pathology of myocardial infarction in the pre- and post-interventional era
Pasotti et al.
Heart 2006;92:1552-1556.
FULL TEXT  

Thrombus Aspiration Before Primary Angioplasty Improves Myocardial Reperfusion in Acute Myocardial Infarction: The DEAR-MI (Dethrombosis to Enhance Acute Reperfusion in Myocardial Infarction) Study
Silva-Orrego et al.
J Am Coll Cardiol 2006;48:1552-1559.
ABSTRACT | FULL TEXT  

Narrative review: reperfusion strategies for ST-segment elevation myocardial infarction.
Ting et al.
ANN INTERN MED 2006;145:610-617.
ABSTRACT | FULL TEXT  

Percutaneous Coronary Intervention After Fibrinolysis: A Multiple Meta-Analyses Approach According to the Type of Strategy
Collet et al.
J Am Coll Cardiol 2006;48:1326-1335.
ABSTRACT | FULL TEXT  

Beneficial effects of abciximab in patients with primary percutaneous intervention for acute ST segment elevation myocardial infarction in clinical practice
Heer et al.
Heart 2006;92:1484-1489.
ABSTRACT | FULL TEXT  

Aspiration thrombectomy and primary percutaneous coronary intervention
De Luca et al.
Heart 2006;92:867-869.
ABSTRACT | FULL TEXT  

Three-year duration of benefit from abciximab in patient receiving stents for acute myocardial infarction in the randomized double-blind ADMIRAL study: reply
Montalescot
Eur Heart J 2006;27:1509-1509.
FULL TEXT  

The Year in Interventional Cardiology
Dixon et al.
J Am Coll Cardiol 2006;47:1689-1706.
FULL TEXT  

Impact of Routine Stenting on Clinical Outcome in Diabetic Patients Undergoing Primary Angioplasty for ST-Segment Elevation Myocardial Infarction
De Luca et al.
Diabetes Care 2006;29:920-923.
FULL TEXT  

The role of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention for ST elevation myocardial infarction
Svilaas et al.
Eur Heart J 2005;26:2479-2481.
FULL TEXT  

Part 5: Acute Coronary Syndromes
Circulation 2005;112:III-55-III-72.
FULL TEXT  

Abciximab in the Treatment of ST-Segment Elevation Myocardial Infarction
Tan et al.
JAMA 2005;294:1760-1761.
FULL TEXT  

Efficacy of primary PCI: the microvessel perspective
Ferenc and Neumann
Eur Heart J Suppl 2005;7:I4-I9.
ABSTRACT | FULL TEXT  

The use of GP IIb/IIIa inhibitors into new perspectives: pre-catheterization laboratory administration
Beygui and Montalescot
Eur Heart J Suppl 2005;7:I10-I14.
ABSTRACT | FULL TEXT  

The role of thrombectomy and embolic protection devices
Dudek et al.
Eur Heart J Suppl 2005;7:I15-I20.
ABSTRACT | FULL TEXT  

Patient selection bias in primary percutaneous coronary intervention trials: a critical issue
Migliorini and Antoniucci
Eur Heart J Suppl 2005;7:I21-I26.
ABSTRACT | FULL TEXT  

Clopidogrel for Percutaneous Coronary Revascularization: Time for More Pretreatment, Retreatment, or Both?
Moliterno and Steinhubl
JAMA 2005;294:1271-1273.
FULL TEXT  

Reperfusion in acute myocardial infarction
DTB 2005;43:49-53.
ABSTRACT | FULL TEXT  

The Benefits of Abciximab in STEMI Patients
Journal Watch Cardiology 2005;2005:3-3.
FULL TEXT  

What's new in the other general journals
Tonks
BMJ 2005;330:927-928.
FULL TEXT